Ribo and Ribocure Form Global Licensing Deal with Madrigal for siRNA Therapies

Ribo and Ribocure Join Forces with Madrigal Pharmaceuticals

On February 11, 2026, the innovative biopharmaceutical companies Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB announced a significant global licensing agreement with Madrigal Pharmaceuticals, Inc. This partnership focuses on the development of novel small interfering RNA (siRNA) therapies aimed at treating metabolic dysfunction-associated steatohepatitis (MASH).

The Significance of MASH

MASH, previously referred to as nonalcoholic steatohepatitis (NASH), represents a critical liver condition with serious potential complications, including cirrhosis and liver cancer. The disease has gained notable attention as a leading cause of liver transplants in women and the second overall cause in the United States. Its prevalence is swiftly increasing, necessitating urgent and effective treatment solutions.

Under the terms of the agreement, Ribo has granted Madrigal exclusive global rights to develop, manufacture, and commercialize a range of siRNA assets. This will include utilizing Ribo's sophisticated liver-targeting siRNA platform, GalSTARTM, to create groundbreaking MASH therapies. Ribo is set to receive an upfront payment of $60 million, with the potential for additional payments exceeding $4.4 billion contingent on the achievement of specific development and commercialization milestones.

An Exciting Partnership

The partnership marks a promising collaboration in the fight against liver diseases. Dr. Zicai Liang, CEO of Ribo, expressed enthusiasm about working with Madrigal, highlighting the combination of their expertise in siRNA technology with Madrigal's extensive knowledge in the field. Dr. Li-Ming Gan, CEO of Ribocure and co-CEO of Ribo, underscored the opportunity to expand the therapeutic landscape for MASH, particularly in light of the rising disease prevalence.

The agreement also allows for potential collaboration on other siRNA programs, including bi-specific agents that can target multiple disease-causing genes simultaneously. Such advancements could lead to more effective treatments tailored to the specific needs of patients suffering from MASH.

Financial Implications

The financial structure of the deal indicates a strong outlook for both companies. In addition to the initial payment, Ribo will benefit from cumulative payments up to $4.4 billion as various milestones are met, along with royalties based on net sales. This reinforces the financial viability and anticipated market impact of the new therapies.

Commitment to Innovation

Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals are dedicated to harnessing the power of RNA interference (RNAi) technology to develop critical nucleic acid-based drugs. They have built a robust pipeline of innovative therapeutics aimed at addressing serious medical needs. This licensing agreement aligns perfectly with their mission to improve patient outcomes through cutting-edge science and technology.

Meanwhile, Madrigal Pharmaceuticals stands out as a pioneering entity in the biopharmaceutical sector, particularly recognized for developing Rezdiffra (resmetirom), the world’s first approved drug specifically targeting MASH. This unique medication not only exemplifies Madrigal’s expertise but also highlights the high unmet medical needs associated with the disease, driving forward the urgency for viably effective treatments.

Conclusion

The collaboration between Ribo, Ribocure, and Madrigal Pharmaceuticals heralds a new era for treatments targeting MASH. With thorough research, innovative technology, and a commitment to addressing medical challenges, this alliance is poised to reshape the landscape of liver disease management, offering hope to countless patients facing these life-threatening conditions. As the condition continues to rise in prevalence, breakthroughs from this partnership could lead to significant advancements in patient care and therapeutic strategy in the ever-evolving landscape of liver health.